K Number
K182456
Device Name
Study Watch
Date Cleared
2019-01-17

(132 days)

Product Code
Regulation Number
870.2920
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Study Watch is intended to record, store, transfer, and display single-channel electrocardiogram (ECG) rhythms. The Study Watch is intended for use by healthcare professionals, adult patients (22 years or older) with known or suspected heart conditions, and health conscious individuals.
Device Description
The Study Watch is a miniaturized physiological data monitoring device that is intended to record, store, transfer and display single-channel electrocardiogram (ECG) rhythms. The device utilizes a band and proprietary watch that incorporates two dedicated sensing electrodes to obtain a single-channel ECG measurement. In practice, a healthcare professional (HCP) may prescribe the Study Watch to a patient and recommend the capture and transmission of one or more ECG rhythms on a daily basis for analysis by the HCP. The patient uses prompts provided on the graphical user interface (GUI) of the watch to collect a real-time 60-second ECG measurement. While an animated ECG waveform is briefly displayed on the GUI of the watch, the patient will not have direct access to the collected waveform. Using the provided charging dock (Cradle) and Verily's Study Hub device, the ECG measurements are securely transferred to Verily's cloud server and are viewed by the HCP using a web portal. The web portal is solely intended for use by the HCP to view time-stamped ECG waveforms collected by the patient and does not include any analysis features. Collectively, the Study Watch consists of the wearable watch and band, the Study Hub (used to transfer data from the watch to the cloud), a Cradle, and the web portal.
More Information

Not Found

No
The description focuses on data acquisition, storage, transfer, and display without mentioning any analytical or interpretive functions performed by the device itself using AI/ML. The analysis is explicitly stated to be performed by the healthcare professional using a web portal that "does not include any analysis features."

No.
The device's intended use is to "record, store, transfer, and display single-channel electrocardiogram (ECG) rhythms" for monitoring and diagnostic purposes, not for direct treatment or therapy.

Yes

The device records and displays single-channel ECG rhythms for healthcare professionals to view, which is used for assessing known or suspected heart conditions. This data collection serves as a tool for diagnosis, even though the device itself doesn't perform automated analysis or provide a diagnostic output to the patient.

No

The device description explicitly states that the Study Watch consists of a wearable watch and band, the Study Hub, a Cradle, and a web portal. This includes hardware components beyond just software.

Based on the provided information, the Study Watch is not an In Vitro Diagnostic (IVD) device.

Here's why:

  • IVD Definition: IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
  • Study Watch Function: The Study Watch directly measures electrical activity of the heart (ECG) from the surface of the skin. It does not analyze biological specimens.
  • Intended Use: The intended use is to record, store, transfer, and display ECG rhythms for use by healthcare professionals and individuals. This is a physiological measurement, not an analysis of a biological sample.

Therefore, the Study Watch falls under the category of a physiological monitoring device, not an IVD.

N/A

Intended Use / Indications for Use

The Study Watch is intended to record, store, transfer, and display single-channel electrocardiogram (ECG) rhythms. The Study Watch is intended for use by healthcare professionals, adult patients (22 years or older) with known or suspected heart conditions, and health conscious individuals.

Product codes (comma separated list FDA assigned to the subject device)

DXH, DPS

Device Description

The Study Watch is a miniaturized physiological data monitoring device that is intended to record, store, transfer and display single-channel electrocardiogram (ECG) rhythms. The device utilizes a band and proprietary watch that incorporates two dedicated sensing electrodes to obtain a single-channel ECG measurement. In practice, a healthcare professional (HCP) may prescribe the Study Watch to a patient and recommend the capture and transmission of one or more ECG rhythms on a daily basis for analysis by the HCP. The patient uses prompts provided on the graphical user interface (GUI) of the watch to collect a real-time 60-second ECG measurement. While an animated ECG waveform is briefly displayed on the GUI of the watch, the patient will not have direct access to the collected waveform. Using the provided charging dock (Cradle) and Verily's Study Hub device, the ECG measurements are securely transferred to Verily's cloud server and are viewed by the HCP using a web portal. The web portal is solely intended for use by the HCP to view time-stamped ECG waveforms collected by the patient and does not include any analysis features. Collectively, the Study Watch consists of the wearable watch and band, the Study Hub (used to transfer data from the watch to the cloud), a Cradle, and the web portal.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Left hand fingers to right wrist or vice versa

Indicated Patient Age Range

adult patients (22 years or older)

Intended User / Care Setting

healthcare professionals, adult patients (22 years or older) with known or suspected heart conditions, and health conscious individuals.
Mobile/active users at rest (ambulatory)

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Clinical performance testing was conducted to demonstrate that the Study Watch generates data that meets the clinical quality requirements for an accurate ECG waveform display. The presented data shows qualitative clinical equivalence and inter-beat interval Bland-Altman analysis with Bias of 1.2ms and 95% limits-of-agreement

§ 870.2920 Telephone electrocardiograph transmitter and receiver.

(a)
Identification. A telephone electrocardiograph transmitter and receiver is a device used to condition an electrocardiograph signal so that it can be transmitted via a telephone line to another location. This device also includes a receiver that reconditions the received signal into its original format so that it can be displayed. The device includes devices used to transmit and receive pacemaker signals.(b)
Classification. Class II (performance standards).

0

Image /page/0/Picture/0 description: The image contains the logos of the U.S. Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the FDA acronym in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

January 17, 2019

Verily Life Sciences LLC Shilpa Mydur Sr. Principal, Regulatory Affairs 269 E Grand Avenue South San Francisco, California 94080

Re: K182456

Trade/Device Name: Study Watch Regulation Number: 21 CFR 870.2920 Regulation Name: Telephone Electrocardiograph Transmitter And Receiver Regulatory Class: Class II Product Code: DXH, DPS Dated: December 20, 2018 Received: December 20, 2018

Dear Shilpa Mydur:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

1

801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice

(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Jessica E. Paulsen -S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K182456

Device Name Study Watch

Indications for Use (Describe)

The Study Watch is intended to record, store, transfer, and display single-channel electrocardiogram (ECG) rhythms. The Study Watch is intended for use by healthcare professionals, adult patients (22 years or older) with known or suspected heart conditions, and health conscious individuals.

Type of Use (Select one or both, as applicable)
-------------------------------------------------
☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)
---------------------------------------------------------------------------------------------------------------------------------------------------------

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

510(k) Summary -Study Watch

Date Prepared:January 11, 2019
Submitter:Verily Life Sciences LLC
Official Contact:Shilpa Mydur
Sr. Principal, Regulatory
Affairs 269 E Grand Ave
South San Francisco, CA 94080, USA
Telephone: +1-415-736-0652
Fax: +1650-618-1499
E-Mail: smydur@google.com
Proprietary Name:Study Watch
Common Name:Telephone Electrocardiograph Transmitter and Receiver
Classification:Class II Medical Device
Requlation Number: 21 CFR 870.2920
Product Code: DXH, DPS
Predicate Device:AliveCor Kardia Band (K171816)
Reason For Submission:New Device

Indications for Use

The Study Watch is intended to record, store, transfer, and display single-channel electrocardiogram (ECG) rhythms. The Study Watch is intended for use by healthcare professionals, adult patients (22 years or older) with known or suspected heart conditions, and health conscious individuals.

Device Description

The Study Watch is a miniaturized physiological data monitoring device that is intended to record, store, transfer and display single-channel electrocardiogram (ECG) rhythms. The device utilizes a band and proprietary watch that incorporates two dedicated sensing electrodes to obtain a single-channel ECG measurement. In practice, a healthcare professional (HCP) may prescribe the Study Watch to a patient and recommend the capture and transmission of one or more ECG rhythms on a daily basis for analysis by the HCP. The patient uses prompts provided on the graphical user interface (GUI) of the watch to collect a real-time 60-second ECG measurement. While an animated ECG waveform is briefly displayed on the GUI of the watch, the patient will not have direct access to the collected waveform. Using the provided charging dock (Cradle) and Verily's Study Hub device, the ECG measurements are securely transferred to Verily's cloud server and are viewed by the HCP using a web portal. The web portal is solely intended for use by the HCP to view time-stamped ECG waveforms collected by the patient and does not include any analysis features. Collectively, the Study Watch consists of the wearable watch and band, the Study Hub (used to transfer data from the watch to the cloud), a Cradle, and the web portal.

4

Image /page/4/Picture/0 description: The image shows the word "verily" in red font. The font is a sans-serif font, and the letters are all lowercase. There is a line underneath the "ve" in the word. The background is white.

Substantial Equivalence Discussion

The Study Watch has the following similarities to the previously cleared predicate device:

  • Similar Intended Use A
  • ♪ Similar Technological Characteristics
  • ハ Similar Performance Specifications

A comparative summary of the technological characteristics of the Study Watch with the predicate device AliveCor Kardia Band (K171816) is presented below:

CharacteristicAliveCor Kardia Band (K171816)Study Watch (New Device)
Indications for
UseThe Kardia Band System is intended to
record, store and transfer single-channel
electrocardiogram (ECG) rhythms. The
Kardia Band System also displays ECG
rhythms and detects the presence of
atrial fibrillation and normal sinus rhythm
(when prescribed or used under the care
of a physician). The Kardia Band
System is intended for use by
healthcare professionals, adult patients
with known or suspected heart
conditions, and health conscious
individuals.The Study Watch is intended to record,
store, transfer, and display single-
channel electrocardiogram (ECG)
rhythms. The Study Watch is intended
for use by healthcare professionals,
adult patients (22 years or older) with
known or suspected heart conditions,
and health conscious individuals.
Product CodeDXH, DPSDXH, DPS
Mechanism of
ActionUser completes circuit with skin contact
and hardware transmits audio signal to
MCP to convert and display ECG
waveformUser completes circuit with skin contact
and hardware measures ECG
waveform, which is stored and securely
transferred to the cloud via the
proprietary Study Hub
Where UsedMobile/active users at rest (ambulatory)Same
Anatomical SitesLeft hand fingers to right wrist or vice
versaSame
Data Acquisition:
Frequency
Response0.5 Hz - 40 Hz0.16 Hz - 40 Hz
ECG ChannelsSingle ChannelSame
Resolution16 bitSame
Sample Rate300 Samples/Second240 Samples/Second

5

Image /page/5/Picture/0 description: The image shows the word "verily" in red font. The font is sans-serif and has a modern, clean look. The letters are evenly spaced and the word is easy to read. There is a red line under the "ve" in the word.

| Memory Capacity | Essentially unlimited due to real-time
transmission to MCP memory (size of
ECG file is miniscule - kilobytes
compared to device memory capacity –
gigabytes) | 512 MB |
|--------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Number of ECG
Leads | Single lead, 2 sensing electrodes | Single lead, 2 sensing electrodes and 1
right-leg drive (RLD) electrode |
| Power Supply:
Battery | 1 Lithium Manganese Dioxide Coin Cells | 1 Lithium Polymer Rechargeable
Battery |
| Battery Life | 100 hours operational | 112 Hours Per Full Charge |
| User Interface: | Lead I, Left to Right | Same |
| Primary Lead | Ultrasonic acoustics | USB |
| Data Acquisition | Apple Watch Band and Sensor | Study Watch |
| Hardware
Software
Interface | Apple iOS based software and Apple
WatchOS based software | Study Watch Graphical User Interface,
Web Portal |
| Physical Specs:
Dimensions | 24.5 x 24.5 x 6.5 mm | 42.6 x 42.3 x 11 mm |
| Weight | 9 grams | 22 grams (without watch band) |
| Prescribed | Prescription and OTC | Prescription |
| Environmental:
Operating Temp
Storage Temp | 10 to 40 degrees C
-20 to 60 degrees C | -5 to 40 degrees C
-25 to 70 degrees C |
| Communications | Ultrasonic Acoustics acquired by watch | USB via Study Hub |

The major differences between the Study Watch and the AliveCor Kardia Band are as follows:

  • Indications for Use: The Indications for Use statement for Study Watch is not identical to that of the predicate device. The intended use of the predicate device includes detection of atrial fibrillation and normal sinus rhythm based on a system analysis of the collected ECG waveform. These analysis features are not present in the Study Watch, and the proposed device is solely intended to record, store, transfer and display ECG waveforms. The Study Watch patient uses the device to record and transfer ECG waveforms to the healthcare provider, but does not have direct access to independently view these data. Accordingly, the Study Watch is only intended for prescription use.

6

K182456

Image /page/6/Picture/1 description: The image shows the word "verily" in red font. The word is lowercase and has a line underneath the "ve" portion of the word. The font is sans-serif and the letters are evenly spaced. The background is white.

  • Δ Data Collection: The Study Watch features a band and proprietary watch that incorporates two dedicated sensing electrodes to enable single-channel ECG measurement. The first of the sensing electrodes is positioned on the top of the watch, and the other sensing electrode is at the bottom of the watch contacting the user's wrist. When the user wears the watch on one wrist and contacts the top of the watch with the other hand, an acquisition loop is created and an ECG measurement is generated. The watch also includes a third electrode known as a right-leq drive (RLD) electrode which functions to reduce electrical interference from the environment to improve signal quality. The predicate device functions similarly to acquire ECG data from two sensing electrodes on a proprietary watch band, but does not incorporate the RLD electrode. The addition of the RLD electrode does not affect the stated intended use or fundamental scientific technology of the proposed device.
  • A Data Transmission: The Study Watch uses a system whereby ECG data is collected by the wearable watch and is then transferred to Verily's Study Hub device via a USB connection to the included charging dock (Cradle). The data are then transferred from the Study Hub to Verily's cloud server for storage using the Study Hub and are then viewed by the HCP using a web portal. The predicate device uses a system that transfers the ECG signal from its electrodes to mobile medical application on the Apple Watch to be analyzed and presented directly to the user.
  • A User Access: For the Study Watch, the ECG data is collected by the patient, but is only viewable in its final form by an HCP using the web portal. The predicate device enables viewing of the ECG waveform data by the patient using a dedicated mobile medical application.

The differences in technological characteristics have been evaluated through performance testing and do not raise any new questions of safety and effectiveness, and therefore the proposed device is substantially equivalent to the predicate device.

Non-Clinical Performance Data

Design validation and verification activities were performed for the Study Watch as a result of the risk analysis assessment and product requirements. Testing included validation of specifications related to software development, sensor performance, stability and material properties. All tests confirmed that the product met the predetermined acceptance criteria. In particular, non-clinical performance testing demonstrated that the Study Watch is substantially equivalent to the predicate device when taking into account its intended use.

The Study Watch was designed and tested in accordance with the applicable requirements in relevant FDA guidance documents and international standards including:

  • ISO 14971 (2012): Medical Devices - Application of Risk Managementto Medical Devices.
  • . IEC 60601-1-2:2014 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests
  • . IEC 60601-1:2005 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance

7

Image /page/7/Picture/0 description: The image shows the word "verily" in red font. The font is sans-serif and the letters are closely spaced together. There is a horizontal line underneath the "ve" in "verily". The word is likely a logo or brand name.

  • . IEC 60601-2-47:2012/ (R)2016 Medical electrical equipment - Part 2-47:Particular requirements for the basic safety and essential performance of ambulatory electrocardiographic systems.
  • IEC 62133 Battery Safety Testing
  • . IEC 62304:2006 Medical device software -- Software life cycle processes
  • . ISO 10993-1:2009 Biological evaluation of medical devices -- Part 1: Evaluation and testing within a risk management process
  • . ISTA 2A (2011): Partial Simulation Performance Tests (Packaging). Packaged-Products 150 lb (68 kg) Or Less.

Clinical Performance Data

Clinical performance testing was conducted to demonstrate that the Study Watch generates data that meets the clinical quality requirements for an accurate ECG waveform display. The presented data shows qualitative clinical equivalence and inter-beat interval Bland-Altman analysis with Bias of 1.2ms and 95% limits-of-agreement